TY - JOUR
T1 - Brexucabtagene autoleucel
T2 - a breakthrough in the treatment of mantle cell lymphoma
AU - Deshpande, Anagha
AU - Wang, Yucai
AU - Munoz, Javier
AU - Jain, Preetesh
N1 - Publisher Copyright:
Copyright © 2022 Clarivate.
PY - 2022/6
Y1 - 2022/6
N2 - In July 2020, the U.S. Food and Drug Administration (FDA) approved brexucabtagene autoleucel (BA), the first anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed/refractory mantle cell lymphoma (MCL). The pivotal ZUMA-2 trial led to the approval of BA in patients who experienced relapsed disease on prior therapies (chemotherapy and/or Bruton tyrosine kinase [BTK] inhibitors). The FDA approval of BA was based on excellent responses with this therapy in highly refractory patients with MCL, who conventionally had poor outcomes. Longer follow-up data from the ZUMA-2 study have been presented at recent international meetings. As is common with other CAR T-cell therapies in lymphomas, the main toxicities of BA therapy included cytokine release syndrome (CRS), infections, cytopenias and CAR-associated neurotoxicity. In this review, we provide a summary of the data in the development of BA and its impact on MCL patient survival and future directions.
AB - In July 2020, the U.S. Food and Drug Administration (FDA) approved brexucabtagene autoleucel (BA), the first anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed/refractory mantle cell lymphoma (MCL). The pivotal ZUMA-2 trial led to the approval of BA in patients who experienced relapsed disease on prior therapies (chemotherapy and/or Bruton tyrosine kinase [BTK] inhibitors). The FDA approval of BA was based on excellent responses with this therapy in highly refractory patients with MCL, who conventionally had poor outcomes. Longer follow-up data from the ZUMA-2 study have been presented at recent international meetings. As is common with other CAR T-cell therapies in lymphomas, the main toxicities of BA therapy included cytokine release syndrome (CRS), infections, cytopenias and CAR-associated neurotoxicity. In this review, we provide a summary of the data in the development of BA and its impact on MCL patient survival and future directions.
KW - Anti-CD19 therapies
KW - Brexucabtagene autoleucel
KW - Cancer immunotherapy
KW - Chimeric antigen receptor (CAR) T-cell therapy
KW - Hematologic malignancies
KW - Mantle cell lymphoma
KW - Non-Hodgkin lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85131771511&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131771511&partnerID=8YFLogxK
U2 - 10.1358/dot.2022.58.6.3378055
DO - 10.1358/dot.2022.58.6.3378055
M3 - Review article
C2 - 35670706
AN - SCOPUS:85131771511
SN - 1699-3993
VL - 58
SP - 283
EP - 298
JO - Drugs of Today
JF - Drugs of Today
IS - 6
ER -